Changes in weight and body fat after use of tetracycline and  Lactobacillus gasseri in rats by Marciano, Jorge José et al.
Braz. J. Pharm. Sci. 2017;53(1):e16059 Page 1 / 7







*Correspondence: F. S. Del Fiol. Universidade de Sorocaba. Rodovia 
Raposo Tavares, Km 92,5 - 18023-000 - Sorocaba - SP, Brasil. Telefone: 
55 15 996170589 - Fax: 55 15 21017074. E-mail: fernando.fiol@prof.uniso.br
Changes in weight and body fat after use of tetracycline and 
Lactobacillus gasseri in rats
Jorge José Marciano, Fernando de Sá Del Fiol*, Alessandra Cristina Marciano Tardelli Ferreira, 
Maria Cláudia Marques, Luciane Lopes Santana
Pharmacology Department, University of Sorocaba, Sorocaba, SP, Brazil
Recent studies have shown a role of intestinal microbiota in obesity. The consumption of antibiotics 
in the last 70 years has led to changes in intestinal microbiota, which has led to weight gain and body 
fat accumulation. To evaluate the possibility of weight gain induced by antibiotics and the possible 
protective effect of probiotics, we divided 45 animals (Rattus norvegicus) into groups and administered 
the following treatments over two weeks: tetracycline, tetracycline + Lactobacillus gasseri, and NaCl. 
The animals were weighed over the course of 8 weeks, and at the end of the treatment period, they were 
measured and subjected to bioelectrical impedance analysis. The results show that the group receiving 
tetracycline alone had a higher body mass index (p=0.030), a greater Lee index (p=0.008), and a lower 
body water percentage than the control group, indicating a greater accumulation of body fat. The group 
receiving the probiotics with tetracycline presented similar results to the control group, indicating a 
possible protective effect of body fat accumulation in the group receiving tetracycline alone. The results 
show that tetracycline increased the concentration of body fat, and the use of probiotics was associated 
with an ability to protect the animals from the pro-obesity effect.
Uniterms: Antimicrobials/evaluation. Obesity/tests. Gut microbiota/tests. Tetracyclines.
INTRODUCTION
Obesity is currently one of the greatest global public 
health challenges, and the number of obese people has 
risen dramatically, especially in Western countries (Riley 
et al., 2013). In the United States alone, the number of 
overweight people has doubled from an average of 15.1% 
of the population in 1976–1980 to 31.2% in 2001–2004 
(Christian, Rashad, 2009). Obesity is associated with 
other grave medical conditions, such as cancer, diabetes, 
hypertension, and cardiovascular disease. Diet and 
physical inactivity are certainly important causes of 
obesity, but they are not the only ones. The multifactorial 
etiology of obesity (Newnham et al., 2009; Riley et al., 
2013) also includes changes in the human microbiota 
(Musso, Gambino, Cassader, 2011; Moreira et al., 2012; 
Cho et al., 2012; Million et al., 2013; Riley et al., 2013; 
Martinez, 2014).
The human gut microbiota has about 100 trillion 
bacterial cells that predominantly belong to four bacterial 
phyla: Proteobacteria, Actinobacteria, Firmicutes, and 
Bacteroidetes. The latter two represent about 90% of the 
organisms found in the gut microbiota (Tilg, Kaser, 2011; 
Riley et al., 2013). There are 10 times more intestinal 
bacterial cells than the cells that comprise a human adult. 
This large number of microorganisms is associated with 
numerous functions that are developed and mediated by 
gut microbiota and have led some authors to refer to the gut 
microbiota as another human organ (Quigley, 2013; Riley 
et al., 2013; Lankelma et al., 2014; Putignani et al., 2014).
Although relatively stable, the gut microbiota is 
affected by age, gender, geography, diet, and environmental 
factors, such as exposure to antibiotics, especially in 
children and newborns (Backhed et al., 2005; Agans et al., 
2011; Vael et al., 2011; Grzeskowiak et al., 2012; Markle 
et al., 2013; Trasande et al., 2013). There are numerous 
studies related to gut microbiota changes (dysbiosis) 
caused by antibiotics and probiotics, including weight 
modifications in humans and animals (Ley et al., 2006; 
Turnbaugh et al., 2008; Xu et al., 2012; Bibiloni, Pons, 
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Tur, 2013). The relationship between Bacteroidetes and 
Firmicutes seems to be a major factor in the increase or 
decrease of energy gain, although there is no consensus 
on the role of each microorganism in the development of 
obesity or weight loss (Collado et al., 2008; Li et al., 2008; 
Turnbaugh et al., 2009; Schwiertz et al., 2010).
In the last 70 years, we have been exposed to large 
amounts of antibiotics as therapies against infections 
(Van Boeckel et al., 2014), in antibiotic-contaminated 
food (Anderson et al., 2003)2003, or in the large amounts 
dumped into the environment (Sarmah Meyer, Boxall, 
2006). This increased exposure, especially in children, 
may be responsible for the recent obesity epidemic. 
Studies show that increases in body weight caused 
by microbial antibiotics is becoming more frequent, 
particularly when the antibiotic has a broad spectrum 
of activity. Alternatively, the use of probiotics has been 
associated with weight loss and could presumably protect 
against the effect caused by antibiotics in the microbiota 
(Haight, Pierce, 1955; Saiman et al., 2010; Thuny et al., 
2010; Saiman et al., 2012; Trasande et al., 2013).
In a recent meta-analysis involving 88 studies on the 
effect of Lactobacillus species on the weight of animals 
and humans, Million et al. (2012) showed that some 
species were associated with weight gain (L. acidophilus, 
L. ingluviei, and L. fermentum), while others were 
associated with weigh loss (L. plantarum and L. gasseri). 
To discover more information about this phenomenon 
and to search for possible treatments with a combination 
of probiotics, this study evaluated the influence of 
tetracycline with or without a probiotic on the weight and 
body composition of rats.
METHODS
Animal care: We used 45 male rats (Rattus 
norvegicus Wistar) that were 15 days old. The animals 
were housed in the animal house at the University of 
Sorocaba, where they stayed for a 10-day adaptation 
period before the experimental phase. They were fed with 
standard rodent chow (Presence®) and water ad libitum. 
The project was approved by the Ethics Committee 
on Animal Research of the University of Sorocaba 
(n.010/2013), and it was conducted in accordance with the 
Brazilian Regulations for Animal Experimentation. The 
animals were housed in cages holding 3 rats each with free 
access to chow and water. They were exposed to a cycle of 
12 hours of light and 12 hours of dark and kept at 22 °C. 
Treatment: The animals were divided into 3 groups 
of 15 animals each: the TETRA Group, the TETRA+LG 
Group, and the CONTR Group. The treatments were given 
to each group once daily by an oral route using a gavage 
needle. TETRA was given a tetracycline dose of 75 mg/
kg/day; TETRA+LG was given a dose of tetracycline of 
75 mg/kg/day followed 2 hours later by treatment with a 
0.1-mL suspension containing 109 cfu of L. gasseri (ATCC 
33323). The CONTR group was given 0.1 mL of NaCL 
solution (0.9%). The treatments were given for two weeks 
on days 0, 2, 4, 7, 9, and 11. The L. gasseri was dissolved 
in a saline solution containing 0.9% NaCL.
Probiotic: L. gasseri was obtained in a lyophilized 
form from the André Tosello Foundation (ATCC 33233 
(American Type Culture Collection)) and maintained and 
grown in MRS BROTH (DE MAN, Rogosa, SHARPE).
Weight gain and body composition
Animal weight (AW): The rats were weighed weekly 
for 8 weeks on days 0, 7, 14, 21, 28, 35, 42, 49, and 56. 
To assess body composition, the rats were measured and 
subjected to bioelectrical impedance analysis.
Body measurements: To measure the bodies of the 
animals, they were anesthetized with sodium pentobarbital 
(30 mg/kg) and measured as described previously.
(Novelli et al., 2007) Abdominal circumference (AC) was 
measured immediately anterior to the forefoot, thoracic 
circumference (TC) was measured immediately behind the 
foreleg, and body length (BL) was the nose–anus length. 
We used a non-elastic strap with an accuracy of 0.1 cm.
Bioelectrical impedance: Tetrapolar bioelectrical 
impedance analysis (TBIA) was performed according to a 
previously described procedure (Hall, Lukaski, Marchello, 
1989) Whole-body reactance (WBXc) and whole-body 
resistance (WBR) were measured using a tetrapolar 
phase-sensitive bioelectrical impedance analyzer that 
introduced a 42-µA current at 50 kHz (Bioelectrical 
Body Composition Analyzer, Model: Quantum II). The 
anesthetized animals were placed in a prone position on 
a nonconductive surface. The hair was removed, and four 
electrodes (two sources and two detectors) made from 
hypodermic needles were placed as described previously 
(Hall, Lukaski, Marchello, 1989; Yokoi et al., 2001). 
Electrode 1 (a source) was placed at the anterior edge of 
the orbit, electrode 2 (a source) was placed 4 cm from the 
base of the tail, electrode 3 (a detector) was placed at the 
anterior opening of the pinna, and electrode 4 (a detector) 
was placed at the midpelvis.
We evaluated the following parameters for all 
animals using the data obtained from the TBIA (WBXc 
and WBR), the body measurements (AC, TC, and BL), 
and the animal weights (AW):
- The body mass index (BMI) was calculated by divid-
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ing the weight of the animal in grams (AW) by the 
square of its length in centimeters (BL) (Novelli et 
al., 2007).
- The Lee index was determined by dividing the cu-
bic root of the animal weight in grams (AW) by the 
length in centimeters (BL) (Bernardis, 1970).
- The AC/TC ratio was determined by dividing the 
AC in centimeters by the TC in centimeters.
- The total body water in grams (TBW) was estimated 
using a previously described empirical formula 
(Hall, Lukaski, Marchello, 1989), TBW = 15.47 + 
97.44 BL2/WBR, where BL is the body length in 
centimeters and WBR is in Ω and obtained from the 
TBIA.
- The percentage of body water (% BW) was calcu-
lated by dividing the TBW in grams by the animal 
weight in grams (AW) and multiplying the result by 
100.
Statistical analysis
All measurements were taken twice. The statistical 
significance between the three groups was calculated using 
a two-way analysis of variance (ANOVA), followed by 
the Tukey-Kramer test. A difference between groups was 
considered statistically significant when the p value was 
<0.05.
RESULTS
Weight Gain: The rats were weighed weekly. Table 
I shows the initial weight average (day zero), the final 
weight medians (day 56), the average weight gain, and the 
standard deviation. We observed no difference in weight 
gain among the three groups.
The data in Figure 1 show that there was no variation 
in the weekly weight of the animals in any of the groups. 
The animals in all groups showed a fairly homogenous 
weight gain, with higher gain between the third and 
fourth weeks after the beginning of the experiment. Table 
II shows the results of the bioelectrical impedance for 
the WBXc and the WBR data. There was no difference 
between any groups tested in the bioelectrical impedance 
parameters evaluated.
Table III shows the results obtained from the body 
measurements and TBIA. The BMI was significantly 
higher in the TETRA group than in the CONTR group 
(p=0.0302). The Lee index was significantly higher in the 
TABLE I - Initial weight, final weight, and weight gain of animals [mean (± SD)] for each group
TETRA TETRA+LG CONTR p
Initial weight (g) 74.05 (±5.11)a 77.53 (±7.94)a 76.33 (±3.84)a 0.7161
Final weight (g) 336.06 (±11.34)a 336.53 (±14.78)a 332.46 (±10.09)a 0.8835
Weight gain (g) 261.13 (±7.38)a 259.00 (±11.66)a 256.13 (±7.63)a 0.7538
TETRA – Tetracycline group (75 mg/kg/day); TETRA+LG – Tetracycline plus L.gasseri group (75 mg/Kg/day plus 109 cfu); 
CONTR – Control group; Different superscripted letters, in same row, indicate statistical significance p<0.05.
FIGURE 1 - Weekly average weight gain (g) and standard deviation.
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TETRA group (which received only tetracycline) than the 
TETRA+LG and CONTR groups (p=0.0082), but there 
was no difference between the TETRA+LG and CONTR 
groups. The results for the AC/TC ratio were similar to 
BMI, showing a difference between only the TETRA 
group and the CONTR group (p=0.0144).
The TBW and the BW results showed that the 
TETRA group, which received only the antibiotic, 
had a lower amount of body water (252.1 g) and the 
lowest percentage of body water (76.42%), indicating 
a greater amount of fat (p=0.0024 and p=0.0052). The 
administration of L. gasseri associated with tetracycline 
in the TETRA+LG group was able to protect against the 
accumulation of body fat that occurred in the TETRA 
animals with similar performance to the CONTR group.
DISCUSSION
Data from this study show that the animals treated 
with tetracycline alone had significantly lower body water 
percentage than the other groups, although the weight 
gain was equal for all groups. Other studies have shown 
similar results. Cho used a different methodology and 
showed that giving animals antibiotics increased their 
body fat, despite not finding differences in weight (Cho 
et al., 2012). There is ample evidence showing that the 
use of antibiotics may be causing weight gain in humans, 
especially when administered to children (Perrini, 1951; 
Macdougall, 1957; Garly et al., 2006; Southern et al., 
2012; Trasande et al., 2013).
This adverse effect should not limit the use of 
antibiotics. During the first years of life when respiratory 
infections most often occur, antibiotic use is more frequent 
and necessary (Razon et al., 2005; Del Fiol et al., 2013). 
However, the use of antibiotics in this age group is a great 
concern because the microbiotas are more susceptible 
to changes (dysbiosis) at this time (Li, Wang, Donovan 
2014; Voreades, Kozil, Weir, 2014). Therefore, it is very 
important to understand that probiotics could provide 
protection against the adverse effects of antibiotics and 
protect the microflora of these children during antibacterial 
therapy. L. gasseri could be used as an alternative to 
protect against dysbiosis and the resulting weight gain.
Studies of L. gasseri in humans have shown 
decreases in abdominal adiposity, body weight, and 
waist and hip circumferences after oral use of probiotics 
(Kadooka et al., 2010; Jung et al., 2013). Several studies 
show that the use of this microorganism in rats decreased 
visceral fat by enhancing lipid excretion (Yonejima, 
Ushida, Mori, 2013), reduced adipocyte size (Sato et 
al., 2008; Hamad et al., 2009), and reduced body weight 
(Kang Yun, Park, 2010; Kang et al., 2013).
The role of the microbiota in obesity and interference 
by antibiotics are widely documented. This study has 
demonstrated that tetracycline increases the fat mass of 
treated animals, as in other studies, and that probiotics (L. 
TABLE II - Bioelectrical impedance: whole body reactance (WBXc) and whole body resistance (WBR) for the three groups
TETRA TETRA+LG CONTR p
WBXc 26.67 (±2.35)a 23.00 (±2.38)a 24.40 (±2.30)a 0.1104
WBR 227.03 (±7.00)a 216.67 (±10.89)a 212.87 (±9.74)a 0.1067
WBXc – Whole-body reactance; WBR - Whole-body resistance; TETRA – Tetracycline group (75 mg/kg/day); TETRA+LG – 
Tetracycline plus L.gasseri group (75 mg/kg/day plus 109 cfu); CONTR – Control group; Different superscripted letters, in same 
row, indicate statistical significance p<0.05.
TABLE III - BMI, Lee index, AC/TC ratio, TBW, and BW in all groups
TETRA TETRA+LG CONTR p
BMI (g/cm2) 0.615 (±0.029)a 0.576 (±0.031)a,b 0.562 (±0.019)b 0.0302
Lee index 0.297 (±0.006)a 0.287 (±0.006)b 0.284 (±0.008)b 0.0082
AC/TC ratio 1.16 (±0.032)a 1.121 (±0.035)a,b 1.110 (±0.025)b 0.0144
TBW (g) 252.1 (±13.70)a 280.7 (±12.16)b 288.8 (±15.62)b 0.0024
BW (%) 76.42 (±4.25)a 84.50 (±4.41)b 87.29 (±5.47)b 0.0052
BMI – Body Mass Index; AC/TC ratio – Abdominal Circumference / Thoracic Circumference Ratio; TBW (g) – Total body 
water in grams; BW (%) – Percentage of body water; TETRA – Tetracycline group (75 mg/kg/day); TETRA+LG – Tetracycline 
plus L.gasseri group (75 mg/kg/day plus 109 cfu); CONTR – Control group; Different superscripted letters, in same row, indicate 
statistical significance p<0.05.
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gasseri in this case) could protect the microbiota while 
preventing or decreasing fat accumulation after the use 
of antibiotics. Other studies are necessary to elucidate 
the mechanism by which some probiotics interfere with 
weight loss or gain in order to combat malnutrition and 
obesity, which are two major problems afflicting global 
health.
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